Navigation Links
Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
Date:3/31/2011

ipal investigator in the study, commented, "There is a real need for novel therapies in PBC.  The clinically meaningful results from this study are highly supportive of OCA's potential as an effective new drug. We know now that OCA is effective given both in addition to UDCA and, from this study, when given alone.  The reductions in AP levels were very substantial and occurred within a month.  The effects on IgM and inflammatory markers suggest that OCA may have disease modifying properties."

Intercept's Chief Medical Officer, David Shapiro, MD, commented, "This study involved 20 centers in 7 countries and has given us and the PBC thought leaders involved a better understanding of the potent mechanism of action of OCA.  With the international PBC network we have established, we are well positioned to conduct a Phase III program.  We are currently discussing requirements for approval with FDA and have received guidance from the EMA supportive of our proposed program."

Mark Pruzanski, MD, Intercept's Chief Executive Officer, added, "The remarkable results achieved with OCA treatment in this study, together with the previously announced positive Phase II results with our drug added to UDCA in refractory PBC patients and in diabetic patients with nonalcoholic fatty liver disease, supports OCA's potential as a novel hepatoprotective drug that may help preserve liver function in patients with a variety of chronic liver diseases."

About Obeticholic Acid (OCA or INT-747)

OCA is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid, the natural endogenous FXR agonist. Intercept has announced positive Phase II results from randomized clinical trials in patients with primary biliary cirrhosis (PBC), the most common autoimmune liver disease, and in type 2 diabetics with nonalcoholic fatty liver disease.  These clinical data and OCA's mechanism
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
2. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
3. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
6. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
7. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
8. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
11. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" ... specialty products, announced today that the Company will present at ... 29, 2013 at the Le Parker Meridian hotel, 119 W. ... . The presentation is scheduled to begin at 2:15 ... About Heska Heska Corporation (NASDAQ: HSKA ...
(Date:5/22/2013)... Attorney Advertising -- Bronstein, Gewirtz & Grossman, ... purchasers of the securities of AMAG Pharmaceuticals, Inc. ... investigation focuses on whether the Company and its ... May 22, 2013, Shares of AMAG dropped $2.69 ... announced in regulatory filing that it has been ...
(Date:5/22/2013)... , May 22, 2013 JenaValve Technology, Inc., ... valve implantation (TAVI) systems for the treatment of aortic valve ... J enaValve Eval U ation of Long Term P ... S E vere Ao R tic Stenosis (JUPITER) Registry at ... post-market registry to evaluate five-year long term safety and effectiveness ...
Breaking Medicine Technology:Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4
(Date:5/22/2013)... (PRWEB) May 22, 2013 The Muscular ... against muscular dystrophy at the annual Charlotte Muscle Team ... to help Charlotte-area families living with muscle disease. ... year's event to support MDA families,” said MDA Divisional ... who were partnered with a "Buddy" to make their ...
(Date:5/22/2013)... 22, 2013 Zensah® Compression Apparel released ... article titled "Breast pain while running affects ... could help." According to the article, a British ... substantial amount suffer from breast pain while running but ... the issue. , Zensah emphasizes the importance for ...
(Date:5/22/2013)... study shows there is a gender gap when it ... one that does not appear to exist in ... had higher levels of self-regulation than boys. Self-regulation is ... impulses, follow directions, and persist on a task. It ... in past studies by Oregon State University researchers. ...
(Date:5/22/2013)... 22, 2013 People in the United States ... to water shortages. In much of the world, water shortages ... advocate, Sharon Kleyne. She warns against taking water for granted ... is available so easily in the United States. , Sharon ... Water radio show, heard live or by podcast on World ...
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 ... version of the DePuy Pinnacle Hip Replacement System continue ... Texas Federal Court, Bernstein Liebhard LLP reports. According ... directed DePuy Orthopaedics to produce monitoring reports associated with ... the company’s medical device marketing practices. Plaintiffs maintained ...
Breaking Medicine News(10 mins):Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2Health News:Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners 2Health News:Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners 3Health News:'Boys will be boys' in US, but not in Asia 2Health News:'Boys will be boys' in US, but not in Asia 3Health News:Water Advocate Sharon Kleyne Announces Water Conservation Appreciation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3
... adherence counseling around the time of HIV treatment initiation ... sub-Saharan Africa, according to a recent study in ... of Global Health at University of Washington, who works ... Nairobi, Kenya. The study published March 1 also ...
... By Alan Mozes HealthDay Reporter , WEDNESDAY, March 2 ... may claim bragging rights. But when it comes to the average ... to the north, a new study of adult obesity rates in ... third of all Americans are now obese, beating out Canada by ...
... bright yellow spice from south Asia belonging to the ... and ancient wisdom suggests that it,s also good for ... Aviv University researchers have discovered that turmeric,s active ingredient ... anti-inflammatory drugs used to fight colon cancer when used ...
... WEDNESDAY, March 2 (HealthDay News) -- Hearing loss affects nearly ... than whites to have hearing problems, a new study shows. ... aged 70 and older who took part in the 2005-06 ... them had hearing loss that ranged from mild to severe. ...
... Reporter , TUESDAY, March 1 (HealthDay News) -- Both ... the risk for breast cancer among postmenopausal women, new ... or no connection between breast cancer and smoking, as ... surfacing for the first time, experts noted. "The ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... that the U.S. Food and Drug Administration approves medical ... Many heart-related devices win FDA approval without being adequately ... so. This means that heart valves, pacemakers, ...
Cached Medicine News:Health News:Study in PLoS: Intensive adherence counseling to HIV treatment improves patient outcomes 2Health News:In Battle of the Bulge, Canada Trumps U.S. 2Health News:In Battle of the Bulge, Canada Trumps U.S. 3Health News:In Battle of the Bulge, Canada Trumps U.S. 4Health News:Fighting cancer at your local Indian restaurant 2Health News:Study Finds Smoking Linked to Breast Cancer Risk 2Health News:Study Finds Smoking Linked to Breast Cancer Risk 3Health News:Heart Devices Not Tested Enough in Women: Study 2Health News:Heart Devices Not Tested Enough in Women: Study 3
The Codman anterior cervical plate is designed for immediate internal fixation of the cervical spine following bone grafting procedures....
... system is a family of plates that ... for consistent, reliable fixation of plate to ... backout. This innovative design eliminates the need ... your screws and the swivel ring automatically ...
... a compact and quiet, yet powerful ... psi/8 bar, it provides more power ... noticeable noise reduction. A small, compact ... enhanced ergonomic handpiece to produce a ...
The stereotactic frame has been specifically designed for a radiosurgery procedure and can be used instead of traditional expensive frames....
Medicine Products: